Brazil approves obesity drug banned in US, Europe

Brazil on Tuesday approved the use of an anti-obesity medication, sibutramine, which has been banned in Europe and the United States, officials said.

The National Health Surveillance Agency (Anvisa) said it would halt sales of weight-loss medications which are based on , but allow sibutramine under heightened surveillance.

The drug will be allowed to be prescribed to patients seeking to lose weight but only if they do not have , Anvisa director Dirceu Barbano told the state news agency Agencia Brasil.

But one Anvisa board member, former Agenor Alvares, dissented.

"If a number of countries took this off the market based on scientific evidence, we cannot ignore that evidence," Alvares said.

According to Agencia Brasil, regulators in February proposed the withdrawal of sibutramine, following the lead of Europe and the United States.

The drug, sold in the United States under the name Meridia, was withdrawn in October 2010 after the European Medicines Agency suspended authorization for all anti-obesity medicines containing sibutramine in January that year amid concerns over the cardiovascular risks.

Barbano said however the evidence showed it is possible to use the medication to lose weight and that health risks can be minimized.

add to favorites email to friend print save as pdf

Related Stories

Genes influence effectiveness of weight-loss drug

Oct 01, 2008

Obese patients with a specific genetic make-up lose more weight when taking the weight loss drug sibutramine and undergoing behavioral therapy compared to those without this genetic make-up, reports a new study in Gastroenterology, the of ...

Experimental diet pill shows promise, little risk

Jul 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

FDA scrutinizes weight loss pill from Orexigen

Dec 03, 2010

(AP) -- Scientists for the Food and Drug Administration said Friday a pill to treat obesity from Orexigen Therapeutics Inc. helped patients lose weight, though it didn't meet all the criteria set forth by the agency.

Recommended for you

Using computers to design drugs

8 hours ago

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

13 hours ago

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

New US restrictions on painkiller to take effect

Aug 21, 2014

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

User comments